Keryx Biopharma (KERX) Misses Q4 EPS by 11c

Keryx Biopharma (NASDAQ: KERX) reported Q4 EPS of ($0.36), $0.11 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $5.68 million.

“As we enter 2016, the fundamentals of Auryxia are solid, and we plan to build on that foundation to advance our launch in the U.S.,” said Greg Madison, chief executive officer of Keryx. “Importantly, the data readout expected in early second quarter from the ferric citrate phase 3 label expansion trial will be an important marker of our efforts to help people with pre-dialysis chronic kidney disease. Specifically, we believe that ferric citrate – which, through its novel mechanism of action, delivers iron orally through the body’s natural absorption process – could be the first FDA-approved oral medicine to treat iron deficiency anemia (IDA) in this patient population.”

Keryx expects full year 2016 Auryxia net U.S. product sales to be in the range of $31 to $34 million.

For earnings history and earnings-related data on Keryx Biopharma (KERX) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Vivos Therapeutics (VVOS) Tops Q2 EPS by 6c
• Seritage Growth Properties (SRG) Reports Q2 Loss of $0.13